{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.46G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "46"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "46"
          },
          "Description in input context": "E46K"
        },
        {
          "HGVS": "NM_001126112.3:c.158G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Neurodegenerative disease",
    "MONDO": "N.D."
  },
  "Experiment Method": [
    {
      "Assay Method": "Amyloid polymerization assay",
      "Material used": {
        "Material Source": "In vitro",
        "Material Name": "Recombinant α-synuclein",
        "Description": "Experiments were conducted using recombinant α-synuclein to assess polymerization rates."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.46G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased polymerization efficiency",
          "Result Description": "E46K mutation significantly enhanced amyloid fibril formation compared to wild-type."
        },
        {
          "Variant": "NM_001126112.3:c.158G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced polymerization efficiency",
          "Result Description": "A53T mutation partially inhibited amyloid fibril formation."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed to confirm results."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each experimental condition was tested in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type α-synuclein was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Control experiments without protein were conducted."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA with post-hoc Tukey test for pairwise comparisons."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Amyloid fibril formation within 70-100% of wild-type levels.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Amyloid fibril formation < 50% or > 150% of wild-type levels.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}